| Literature DB >> 28194715 |
Beata Zatorska1, Marion Groger2, Doris Moser3, Magda Diab-Elschahawi4, Luigi Segagni Lusignani4, Elisabeth Presterl4.
Abstract
BACKGROUND: Prosthetic implant infections caused by Staphylococcus aureus and epidermidis are major challenges for early diagnosis and treatment owing to biofilm formation on the implant surface. Extracellular DNA (eDNA) is actively excreted from bacterial cells in biofilms, contributing to biofilm stability, and may offer promise in the detection or treatment of such infections. QUESTIONS/PURPOSES: (1) Does DNA structure change during biofilm formation? (2) Are there time-dependent differences in eDNA production during biofilm formation? (3) Is there differential eDNA production between clinical and control Staphylococcal isolates? (4) Is eDNA production correlated to biofilm thickness?Entities:
Mesh:
Substances:
Year: 2017 PMID: 28194715 PMCID: PMC5498371 DOI: 10.1007/s11999-017-5266-0
Source DB: PubMed Journal: Clin Orthop Relat Res ISSN: 0009-921X Impact factor: 4.176
Fig. 1A–E(A) The S aureus biofilm after 6 hours of incubation shows grape-like groups and suspected eDNA filaments (arrow) before spreading. (B) A magnification is shown of Illustration A, using a filter to better observe the filamentous bonds (arrow). (C) After 24 hours of incubation, a biofilm layer is forming. (D) The S epidermidis biofilm after 6 hours of incubation shows scattered cells over the surface. (E) After 24 hours of incubation, suspected eDNA filaments (arrow) are produced. (Original magnification, ×1000; scale bar: 5 µm).
Fig. 2A–DClinical S epidermidis biofilms after (A) 6 hours and (B) 24 hours, and control isolates of S epidermidis biofilms after (C) 6 hours (D) and 24 hours are shown. The amount of dead cells DNA (red) measured after 6 hours was higher (p < 0.005) on biofilms of clinical isolates of S epidermidis than for control isolates. Generally eDNA (green) production was higher (p < 0.05) on all biofilms of clinical isolates than on control isolates. (Original magnification, ×1000; scale bar: 5 µm).
Amounts of eDNA measured for clinical and control S aureus and S epidermidis
| Type of isolate | DAPI (fluorescence units) | PME (ng/µL) | Confocal laser scanning microscopy mean % area eDNA (TOTO®-1; green)* | |
|---|---|---|---|---|
| 6-hour | 24-hour | |||
|
| 2446 ± 2577 | 74.9 ± 21.6 | 1.61 ± 1.39 | 1.35 ± 2.00 |
|
| 2622 ± 1113 | 89.6 ± 12.7 | 1.62 ± 1.33 | 6.42 ± 10.60 |
| No difference | No difference | No difference | p = 0.01 | |
|
| ||||
| Clinical isolates (n = 30) | 2814 ± 1058 | 84 ± 18.12 | 1.97 ± 1.51 | 1.83 ± 2.30 |
| Control isolates (n = 15) | 1707 ± 720 | 57 ± 16.2 | 0.88 ± 0.72 | 0.38 ± 0.19 |
| p = 0.001 | p = 0.001 | p = 0.002 | p = 0.01 | |
|
| ||||
| Clinical isolates (n = 30) | 2287 ± 647 | 93 ± 8.5 | 1.71 ± 1.07 | 6.98 ± 12.62 |
| Control isolates (n = 15) | 3292 ± 1520 | 83 ± 16.4 | 1.45 ± 1.78 | 5.3 ± 4.57 |
| p = 0.005 | p = 0.005 | No difference | No difference | |
| Clinical isolates (n = 60) | 2551 ± 909 | 88.6 ± 14.8 | 1.84 ± 1.31 | 4.41 ± 9.36 |
| Control isolates (n = 30) | 2500 ± 1419 | 69.6 ± 20.6 | 1.17 ± 1.37 | 2.84 ± 4.04 |
| No difference | p = 0.001 | p = 0.03 | No difference | |
*Cyanine dimer TOTO®-1 to stain extracellular DNA (green); DAPI = 4’,6-diamidino-2-phenylindole; PME = polymer mediated enrichment.
Antimicrobial characteristics of the clinical and control isolates
| Antibiotic resistance | Knee prosthesis | Hip prosthesis | Controls (nose) | Knee prosthesis | Hip prosthesis | Controls (cubital fossa) |
|---|---|---|---|---|---|---|
| Oxacillin resistant | 4 (27%) | 4 (27%) | 0 | 7 (47%) | 8 (53%) | 3 (20%) |
| Rifampicin resistant | 0 | 1 (7%) | 0 | 5 (33%) | 4 (27%) | 0 |
| Ciprofloxacin resistant | 2 (13%) | 5 (33%) | 0 | 7 (47%) | 7 (47%) | 3 (20%) |
| Vancomycin resistant | 0 | 0 | 0 | 0 | 0 | 0 |